The AsepticSure final-phase development program involves four primary progressive steps which include completion of final commercial design and verification, regional regulatory compliance, soft product launch involving small scale manufacturing output and multi-sector market penetration supported by up-scaled output and the ability to outsource macro manufacturing capacity at the appropriate time.

Medizone CEO Edwin Marshall said ADA is a ‘new kid on the block’ – but what the development team behind it brings to the table for the future of AsepticSure, exceeds all of their expectations.

"We’re now more confident than ever that our AsepticSure product line will far surpass any other form of sterilization technology on the market not only in terms of its clinically proven anti-microbial efficacy, but also in its functionality, mobility and cost-effectiveness," Marshall said.